Watch out for snake oil: PGS, “ovarian rejuvenation” and more: July 2017 CHR VOICE Digest

Since there is important new information for infertility patients to be disseminated, we decided to shorten the summer hiatus for the VOICE by, after all, publishing a July issue. This issue will, therefore, among other subjects, address the seemingly never-ending saga of preimplantation genetic screening (PGS), now suddenly given the new name preimplantation genetic testing for aneuploidy (PGT-A) by the American Society for Reproductive Medicine (ASRM), and by us, simply, given the acronym PGS 3.0. We will also address a previously only marginally discussed subject in the VOICE, which in recent months in chat-rooms, however, received increasing attention: the so-called “ovarian rejuvenation.”
In addition, we also have to again note the issue of nuclear transfer (i.e., 3-parent IVF), this time in attempts to treat infertility in older women, since colleagues here in New York City have gone public by announcing the utilization of this technique (without prior approval by the Food and Drug Administration) through a newly-formed start-up company at the startling average price of $100,000 per in vitro fertilization (IVF) cycle. With so much truly challenging news to comment on, we, simply, could not stay quiet in the month of July!

In this issue, we cover:

Read this issue of the CHR VOICE in PDF

Norbert Gleicher, MD, leads CHR’s clinical and research efforts as Medical Director and Chief Scientist. A world-renowned reproductive endocrinologist, Dr. Gleicher has published hundreds of peer-reviewed papers and lectured globally while keeping an active clinical career focused on ovarian aging, immunological issues and other difficult cases of infertility.